Don O. Somers

1.2k total citations
17 papers, 782 citations indexed

About

Don O. Somers is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Don O. Somers has authored 17 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Organic Chemistry and 4 papers in Pharmacology. Recurrent topics in Don O. Somers's work include Melanoma and MAPK Pathways (4 papers), Phosphodiesterase function and regulation (4 papers) and Computational Drug Discovery Methods (3 papers). Don O. Somers is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Phosphodiesterase function and regulation (4 papers) and Computational Drug Discovery Methods (3 papers). Don O. Somers collaborates with scholars based in United Kingdom, United States and Belgium. Don O. Somers's co-authors include W. Michael Panneton, Kenneth Down, Craig Jamieson, David J. Hirst, Vipulkumar K. Patel, Nicholas D. Measom, Eric S. Manas, Ian D. Wall, David Scott Palmer and Margarete Neu and has published in prestigious journals such as Journal of Biological Chemistry, Brain Research and Infection and Immunity.

In The Last Decade

Don O. Somers

17 papers receiving 764 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Don O. Somers United Kingdom 12 412 371 121 107 75 17 782
Katerina Leftheris United States 18 407 1.0× 404 1.1× 104 0.9× 88 0.8× 44 0.6× 34 754
Brian A. Chauder United States 16 332 0.8× 596 1.6× 111 0.9× 62 0.6× 145 1.9× 23 928
Yinghong Gao United States 17 269 0.7× 441 1.2× 110 0.9× 33 0.3× 58 0.8× 25 728
J. Romine United States 19 441 1.1× 362 1.0× 32 0.3× 78 0.7× 124 1.7× 31 1.0k
Jianqi Li China 14 189 0.5× 334 0.9× 51 0.4× 66 0.6× 65 0.9× 58 584
Paul Beswick United Kingdom 20 471 1.1× 443 1.2× 51 0.4× 68 0.6× 89 1.2× 38 1.0k
Allan R. Moorman Italy 22 544 1.3× 726 2.0× 41 0.3× 83 0.8× 161 2.1× 51 1.2k
Eugene L. Piatnitski Chekler United States 13 275 0.7× 387 1.0× 90 0.7× 34 0.3× 29 0.4× 23 660
Youyi Peng United States 15 271 0.7× 298 0.8× 50 0.4× 105 1.0× 77 1.0× 28 685
Andy Merritt United Kingdom 15 224 0.5× 430 1.2× 172 1.4× 88 0.8× 95 1.3× 32 816

Countries citing papers authored by Don O. Somers

Since Specialization
Citations

This map shows the geographic impact of Don O. Somers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don O. Somers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don O. Somers more than expected).

Fields of papers citing papers by Don O. Somers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don O. Somers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don O. Somers. The network helps show where Don O. Somers may publish in the future.

Co-authorship network of co-authors of Don O. Somers

This figure shows the co-authorship network connecting the top 25 collaborators of Don O. Somers. A scholar is included among the top collaborators of Don O. Somers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don O. Somers. Don O. Somers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lewis, Alan J., et al.. (2025). Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody. Heliyon. 12(1). e44247–e44247. 1 indexed citations
2.
Grant, Emma K., Sophie M. Bertrand, Kenneth Down, et al.. (2023). Covalent targeting of non-cysteine residues in PI4KIIIβ. RSC Chemical Biology. 4(12). 1111–1122. 3 indexed citations
3.
Palmer, David Scott, et al.. (2020). Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics. Journal of Chemical Information and Modeling. 60(3). 1528–1539. 95 indexed citations
4.
Somers, Don O., et al.. (2019). Design and Characterization of Protein E-PilA, a Candidate Fusion Antigen for Nontypeable Haemophilus influenzae Vaccine. Infection and Immunity. 87(8). 8 indexed citations
5.
Measom, Nicholas D., Kenneth Down, David J. Hirst, et al.. (2016). Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA 2 Inhibitor. ACS Medicinal Chemistry Letters. 8(1). 43–48. 207 indexed citations
6.
Garton, Neil, Michael D. Barker, Emma J. Jones, et al.. (2016). Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(19). 4606–4612. 8 indexed citations
7.
Harling, John D., Angela M. Deakin, Sébastien Campos, et al.. (2013). Discovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP Pocket. Journal of Biological Chemistry. 288(39). 28195–28206. 23 indexed citations
8.
Mitchell, Charlotte, Stuart P. Ballantine, Diane M. Coe, et al.. (2010). Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR. Bioorganic & Medicinal Chemistry Letters. 20(19). 5803–5806. 34 indexed citations
9.
Down, Kenneth, Paul Bamborough, Catherine M. Alder, et al.. (2010). The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38α MAP kinase. Bioorganic & Medicinal Chemistry Letters. 20(13). 3936–3940. 10 indexed citations
10.
Kranz, Michael, Michael Wall, Afjal H. Miah, et al.. (2009). Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorganic & Medicinal Chemistry. 17(14). 5336–5341. 52 indexed citations
11.
Woodrow, Michael D., Stuart P. Ballantine, Michael D. Barker, et al.. (2009). Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration. Bioorganic & Medicinal Chemistry Letters. 19(5). 1380–1385. 54 indexed citations
12.
Angell, Richard, Paul Bamborough, Jacky B. Buckton, et al.. (2008). Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Bioorganic & Medicinal Chemistry Letters. 18(15). 4428–4432. 63 indexed citations
13.
Hamblin, J., Stuart P. Ballantine, Anthony W. J. Cooper, et al.. (2008). Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(14). 4237–4241. 59 indexed citations
14.
Angell, Richard, Paul Bamborough, Mark J. Bamford, et al.. (2008). Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorganic & Medicinal Chemistry Letters. 18(15). 4433–4437. 52 indexed citations
15.
Bamborough, Paul, et al.. (2008). Kinase array design, back to front: Biaryl amides. Bioorganic & Medicinal Chemistry Letters. 18(19). 5285–5289. 19 indexed citations
16.
Angell, Richard, Paul Bamborough, David Brown, et al.. (2007). Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. Bioorganic & Medicinal Chemistry Letters. 18(1). 324–328. 24 indexed citations
17.
Somers, Don O. & W. Michael Panneton. (1984). Heterogeneity of neurons in the subnucleus interpolaris of the cat. Brain Research. 309(2). 317–333. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katerina Leftheris Breakdown of academic impact, for papers by Brian A. Chauder Breakdown of academic impact, for papers by Yinghong Gao Breakdown of academic impact, for papers by J. Romine Breakdown of academic impact, for papers by Jianqi Li Breakdown of academic impact, for papers by Paul Beswick Breakdown of academic impact, for papers by Allan R. Moorman Breakdown of academic impact, for papers by Eugene L. Piatnitski Chekler Breakdown of academic impact, for papers by Youyi Peng Breakdown of academic impact, for papers by Andy Merritt
Rankless by CCL
2026